Baidu
map

10大静脉溶栓禁忌症,一张图片轻松记!

2021-11-01 深圳市卒中学会 深圳市卒中学会

溶栓酶可直接或间接作用于纤溶系统各环节。纤溶系统由纤溶酶原、纤溶酶、激活酶原和抑制物组成。

溶栓药是促进纤维蛋白溶解而溶解血栓的药。体内纤维蛋白溶解过程是一系列蛋白酶催化连锁反应,第一阶段为血浆或组织中激活剂的活化并转化为纤溶酶原激活剂;第二阶段为纤溶酶原转化为纤溶酶;纤维蛋白或纤维蛋白原被分解。溶栓酶可直接或间接作用于纤溶系统各环节。纤溶系统由纤溶酶原、纤溶酶、激活酶原和抑制物组成。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698287, encodeId=5801169828ebc, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jun 16 17:27:58 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466746, encodeId=99f01466e46d3, content=<a href='/topic/show?id=67f3e463637' target=_blank style='color:#2F92EE;'>#禁忌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74636, encryptionId=67f3e463637, topicName=禁忌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06006859456, createdName=xlxchina, createdTime=Wed Nov 03 05:27:58 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545123, encodeId=d27b15451230f, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Nov 03 05:27:58 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2022-06-16 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698287, encodeId=5801169828ebc, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jun 16 17:27:58 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466746, encodeId=99f01466e46d3, content=<a href='/topic/show?id=67f3e463637' target=_blank style='color:#2F92EE;'>#禁忌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74636, encryptionId=67f3e463637, topicName=禁忌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06006859456, createdName=xlxchina, createdTime=Wed Nov 03 05:27:58 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545123, encodeId=d27b15451230f, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Nov 03 05:27:58 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1698287, encodeId=5801169828ebc, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jun 16 17:27:58 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466746, encodeId=99f01466e46d3, content=<a href='/topic/show?id=67f3e463637' target=_blank style='color:#2F92EE;'>#禁忌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74636, encryptionId=67f3e463637, topicName=禁忌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06006859456, createdName=xlxchina, createdTime=Wed Nov 03 05:27:58 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545123, encodeId=d27b15451230f, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Nov 03 05:27:58 CST 2021, time=2021-11-03, status=1, ipAttribution=)]

相关资讯

Neurology:静脉溶栓时间窗有望扩大到11小时?

2020年3月来自希腊的Georgios Tsivgoulis等在 Neurology 上公布了他们的 meta 分析的结果

Neurology:慢性肾脏病患者的静脉溶栓治疗

中度至重度CKD与IVT治疗的AIS者的ICH风险增加和较差的功能预后有关。

Stroke:替奈普酶静脉溶栓治疗大血管闭塞患者的疗效分析

与接受静脉阿替普酶治疗的患者相比,接受替奈普酶静脉溶栓治疗的LVO急性缺血性卒中患者再通和临床效果显著提高。

JAMA Neurol:院内中风患者血管内再灌注治疗率及功能预后研究

住院脑卒中发病率呈现出上升趋势,与院外脑卒中发作相比,院内发病患者的再灌注延迟时间较长,功能预后较差

NEJM:血管内治疗对基底动脉闭塞卒中患者的疗效及安全性研究

对于基底动脉闭塞卒中患者,血管内治疗与标准卒中治疗手段相比,在改善患者预后方面无显著优势,但本试验不排除血管内治疗的实质益处,需要更大规模的试验来确定血管内治疗对基底动脉阻塞性卒中的有效性和安全性。

Neurology:静脉溶栓发生远隔部位脑出血的原因

尽管增加脑出血(ICH)的风险,但已证实在脑缺血症状发作后的最初4.5小时内IV给予重组组织纤溶酶原激活物(rtPA)的益处。

Baidu
map
Baidu
map
Baidu
map